Global Research, Trusted Science
IASLC’s journals, the Journal of Thoracic Oncology (JTO) and JTO Clinical and Research Reports (JTO CRR), continue to play a central role in advancing and sharing lung cancer research worldwide. In 2025, JTO CRR reached a new milestone with a record-high Impact Factor, reflecting its continued growth and increasing recognition within the global thoracic oncology community. Together, the journals serve as trusted platforms for disseminating high-quality scientific findings, clinical insights, and emerging research.
I would like to share the Journal of Thoracic Oncology’s (JTO) progress with you. The Impact Factor is 20.8. This is a slight decrease from 21.1 last year. The journal remains a “high impact journal” with an IF > 20. The journal ranks third among 108 respiratory medicine journals and remains at 13th among 326 oncology journals. Because of the narrower focus, it is generally difficult for organ-specific oncology journals to make a significant impact in the oncology publishing landscape. With an Impact Factor of 20.8, JTO is the leading journal in thoracic oncology and in the top thirteen of all three hundred and twenty-six cancer journals.”
-Alex A. Adjei, MD, PhD, FACP Editor-in-Chief
Top 10 Most Cited JTO Articles Published in 2025
The JTO Clinical and Research Reports (JTO CRR) soared to new heights, as the impact factor continues to rise.
I am delighted to share with you that the impact factor for JTO Clinical and Research Reports (JTO CRR) is 3.5, an increase from last year’s IF of 3.0. This puts the journal in the top half of oncology journals and in the top third of respiratory journals. This reflects the tremendous support from the IASLC, the journal team as a whole, the remarkable group of Associate Editors, our editorial office team, and all our reviewers.”
-Emily Stone, MBBS, PhD, FRACP Editor-in-Chief, JTO CRR